Which antibiotics can be administered intramuscularly in a patient allergic to penicillins and sulfonamides?

Intramuscular Antibiotics for Patients with Penicillin and Sulfonamide Allergies

In patients allergic to both penicillins and sulfonamides, carbapenems (such as ertapenem or meropenem) and cephalosporins (particularly ceftriaxone) can be safely administered intramuscularly without prior testing or additional precautions.

Primary Recommendations Based on Guidelines

Carbapenems - First-Line Choice

Carbapenems are the safest option and can be given without testing or precautions 1, 2. The evidence strongly supports this approach:

• Cross-reactivity between penicillins and carbapenems is extremely low at 0.87% (95% CI: 0.32%-2.32%) 1
• A prospective study of 211 patients with confirmed penicillin allergy showed 100% tolerated carbapenems 1
• Ertapenem and meropenem are both available for IM administration
• No additional testing or graded challenge is required unless the patient has multiple drug allergies or severe anxiety 1

Cephalosporins - Excellent Alternative

Cephalosporins with dissimilar R1 side chains to penicillins can be administered directly 2:

• Ceftriaxone is the most practical IM cephalosporin option and has dissimilar side chains to most penicillins
• Cross-reactivity risk is <5% in patients with unverified penicillin allergy 1
• The linked probability of reaction is approximately 0.1% 1
• Strong recommendation (moderate quality evidence) for use of cephalosporins with dissimilar side chains 2

Aztreonam (Monobactam)

Aztreonam can be used safely 1, 2:

• No cross-reactivity with penicillins for IgE- or T-cell-mediated hypersensitivity 1
• Available for IM administration
• Caveat: Avoid if patient has specific ceftazidime or cefiderocol allergy due to shared side chains 2

Practical Algorithm for IM Antibiotic Selection

Step 1: Verify allergy severity

• If history of severe delayed reactions (Stevens-Johnson syndrome, hepatitis, nephritis): avoid all beta-lactams 2
• If non-severe or immediate-type reactions: proceed with options below

Step 2: Choose based on clinical scenario

For broad-spectrum coverage:

• First choice: Carbapenem (ertapenem 1g IM daily or meropenem IM)
• Second choice: Ceftriaxone 1-2g IM daily

For gram-positive coverage:

• Ceftriaxone IM
• Consider non-beta-lactam alternatives if needed (see below)

For gram-negative coverage:

• Ceftriaxone IM
• Aztreonam IM (if ceftazidime allergy excluded)

Non-Beta-Lactam IM Options

When beta-lactams must be avoided entirely:

• Aminoglycosides (gentamicin, tobramycin) - IM administration well-established
• Fluoroquinolones - some formulations available for IM use, though less common
• Macrolides - azithromycin has been shown safe in penicillin/cephalosporin allergic patients 3, though IM formulation limited

Critical Caveats

Avoid these common pitfalls:

1. Don't automatically avoid all beta-lactams - the cross-reactivity rates are much lower than historically believed 1, 4

2. Document the specific type of allergic reaction - this determines safety of alternatives:

   • Immediate-type (urticaria, anaphylaxis): carbapenems and cephalosporins with dissimilar side chains are safe
   • Delayed non-severe (rash >1 hour after dose): even broader options available
   • Severe delayed (SCAR): avoid all beta-lactams 2

3. Sulfonamide allergy increases risk - patients with both penicillin AND sulfa allergies have higher rates of reactions to alternative antibiotics (OR 5.4) 5

4. Multiple drug allergies (≥3) increase risk - these patients have 6.4-fold higher odds of reactions to cephalosporins/carbapenems 5 and may benefit from graded challenge in controlled setting

5. Consider penicillin allergy testing - >90% of reported penicillin allergies are not true allergies on testing 6, which would expand antibiotic options significantly

Strength of Evidence

The recommendations prioritize 2023 Dutch SWAB guidelines [2-2 and 2022 AAAAI/ACAAI practice parameter 1 as the most recent, comprehensive guideline evidence. These consistently demonstrate:

• Strong recommendations for cephalosporins with dissimilar side chains (moderate quality evidence)
• Conditional recommendations for carbapenems (moderate quality evidence)
• Conditional recommendations for aztreonam (low quality evidence)

The cross-reactivity data from prospective studies 1, 5, 4 support these guideline recommendations with consistent findings of <1-2% true cross-reactivity rates.